SpO2 Infant and Pediatric Study

N/ANot Yet RecruitingNCT07615738

GE Healthcare180 enrolled

Overview

This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data, performance across skin tones, and user feedback.

This prospective clinical study evaluates a pulse oximetry sensor in hospitalized infants (28 days to 23 months) and children (2-12 years) under routine clinical conditions. The primary objective is to assess the accuracy and agreement of SpO₂ measurements compared with reference SaO₂ values obtained from CO-oximetry analysis of simultaneously drawn arterial blood, using methods aligned with ISO 80601-2-61 (3rd edition CD draft) and FDA draft guidance. Secondary objectives include measuring the proportion of time the device produces invalid or unusable data to assess reliability for clinical use. The safety objective is to collect safety information, including type and number of AEs, SAEs, and device issues. Results may support product development, regulatory submissions, and marketing activities.

Study Type

INTERVENTIONAL

Allocation

Purpose

DEVICE_FEASIBILITY

Masking

NONE

Enrollment

180

Conditions

SpO2 (Peripheral Oxygen Saturation) Measurement Validation SpO2

Interventions

SpO2 SensorDEVICE

SpO2 sensors use red and infrared LED light to estimate the arterial oxygen saturation.

Eligibility

Sex: ALLMin age: 29 DaysMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * subjects are 1-23 months (infant cohort) or 2-12 years old (pediatric cohort) * requiring arterial blood samples per the site's standard of care. Exclusion Criteria: * Fractional Methemoglobinemia (FMetHb \>2%) or Fractional carboxyhemoglobinemia (FCOHb \>3%), within 24 hours of arterial blood draw. * Severe anemia (tHb \<7g/dL) within 4 hours prior to arterial blood gas draw. * Hematocrit (Hct) \<25 within 4 hours prior to arterial blood gas draw. * Patients with injuries, deformities, or abnormalities which may prevent proper application of the sensor. * Patients on Extracorporeal Membrane Oxygenation (ECMO). * Patients receiving point of care (POC) testing for blood gases. * Patients with diseases/conditions that may cause differential (or reverse differential) cyanosis including, but not limited to: * Patent ductus arteriosus with pulmonary arterial hypertension. * Pulmonary hypertension and left-heart abnormalities aortic arch hypoplasia, interrupted aortic arch, critical coarctation, and critical aortic stenosis. * Children with transposition of the great arteries (TGA) and coarctation of the aorta or interrupted aortic arch, and TGA with suprasystemic pulmonary vascular resistance. * At the discretion of the principal investigator or designee due to the subject health condition.

Locations (1)

University of Nebraska Medical Center Children's Hospital

Omaha, Nebraska, United States

Outcomes

Primary Outcomes

Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 values

The collection of SpO2 percentage sensor data with simultaneous SaO2 values percentage from each subject enrolled in the study.

Time frame: From enrollment to the end of standard of care arterial cannulation, approximately 1 week.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.